WebDoctor Encyclopedia

Skin Soft-tissue sarcomas

Malignant granular cell tumour

Malignant granular cell tumour is a very rare cancerous form of a usually benign nerve-sheath-related growth. It tends to be larger and grow faster than the benign kind. Wide surgical removal is the main treatment, and close follow-up is needed because it can spread.

Medically reviewed Last reviewed October 20, 2026

What is a malignant granular cell tumour?

A malignant granular cell tumour is a very rare soft tissue cancer related to the Schwann cells, the cells that wrap around and protect nerves. Its cells are packed with tiny granules that make them look grainy under the microscope, which gives the tumour its name.

Granular cell tumours themselves are not unusual. They often appear as small, firm lumps in the skin, tongue, breast or other soft tissues, and the great majority are benign. Only a small proportion, usually estimated at 1-2%, are malignant. These malignant forms behave like a high-grade sarcoma, with a tendency to return locally and to spread to lymph nodes, lungs and bone (Fanburg-Smith et al., 1998).

Telling a malignant granular cell tumour from a benign one can be difficult. Pathologists use a set of microscope criteria, described in 1998, together with the size and behaviour of the tumour. In practice, spread to other organs remains the only certain proof of malignancy (Nasser et al., 2011).

The main treatment is wide surgical removal. Radiotherapy and drug treatments are used in some cases, but the tumour responds poorly to most chemotherapy. Outlook depends heavily on size and whether the tumour has spread.

1. Key facts at a glance

Feature Details
Type of cancer Soft tissue sarcoma with Schwann cell features
How common Very rare; about 1-2% of granular cell tumours
Typical age Middle age; median 54 years in a registry study
Sex More common in women in registry data
Common sites Soft tissues of the limbs and trunk; also skin and other organs
Typical size Median about 4 cm in registry data
Spread Lymph nodes, lungs, bone and liver
Main treatment Wide surgical excision
Outlook Five-year cause-specific survival about 74% in registry data; poorer with spread or large size

2. Types

The granular cell tumour spectrum

Fanburg-Smith and colleagues proposed six microscope criteria to separate benign, atypical and malignant tumours (Fanburg-Smith et al., 1998).

Criterion What the pathologist looks for
Necrosis Areas of dead tumour tissue
Spindling Elongated, spindle-shaped tumour cells
Vesicular nuclei with large nucleoli Open-looking nuclei with prominent dots
Increased mitoses More than 2 dividing cells per 10 high-power fields
High nuclear-to-cytoplasmic ratio Large nuclei relative to the cell
Pleomorphism Cells of varying size and shape
Category Criteria met Behaviour in the original study
Benign None (focal pleomorphism allowed) No metastases
Atypical One or two No metastases in the original study, but later reports show some can spread
Malignant Three or more High rate of recurrence and metastasis

A simpler approach

A later study suggested that two features, necrosis and increased mitoses, could identify potentially aggressive tumours just as well as the six criteria. The proliferation marker Ki-67 may help in difficult cases (Nasser et al., 2011).

Granular cell tumours in different places

Site Notes
Skin and under the skin The most common site for benign tumours
Tongue and mouth Common site for benign tumours
Breast Can mimic breast cancer on scans
Deep soft tissue of limbs and trunk More typical of malignant tumours
Internal organs Oesophagus, larynx and others

3. Causes and risk factors

The cause is not known.

Factor Notes
Age Mostly adults in middle age
Sex Registry data show more women; one pathology series found malignant cases mostly in men
Previous benign granular cell tumour Rarely, a malignant tumour appears at the site of an earlier one
Inherited syndromes Multiple granular cell tumours have been linked with rare syndromes, but most cases are sporadic
Lifestyle No known link

4. How does it look

On examination

Feature Description
Lump Firm, often deep, sometimes painful
Size Often larger than benign granular cell tumours
Growth Steady growth or sudden enlargement
Skin Usually normal over deep tumours; ulceration in some

On scans

Test Purpose
MRI Size, depth and relation to nerves and vessels
CT of the chest Looks for lung spread
PET-CT Shows spread to lymph nodes and other organs
Ultrasound First test for many lumps; guides biopsy

Under the microscope

Feature Description
Cells Large cells with abundant granular pink cytoplasm
Stains S-100 protein, SOX10, CD68 and neuron-specific enolase positive
Ki-67 Higher in malignant tumours
p53 Often strongly expressed in malignant tumours

In the original study of 73 tumours, almost all expressed S-100 protein, and a Ki-67 index above 10% was linked with poorer survival (Fanburg-Smith et al., 1998).

Why diagnosis is challenging

Granular cell tumours are usually benign and slow-growing, so a small biopsy may not show the features of malignancy, which can be patchy. Pathologists therefore prefer to examine the whole tumour after removal. Even then, some tumours sit in a grey zone: they look atypical but not clearly malignant. A Japanese study found that some atypical tumours did spread, so these patients need careful follow-up (Imanishi et al., 2016).

Doctors also look at the clinical picture. A large tumour, deep location, rapid growth or recurrence after removal raises concern, even if the microscope findings are borderline. Discussion at a sarcoma multidisciplinary meeting brings these pieces of information together.

5. Symptoms

Common symptoms

  • A firm lump in the thigh, arm, trunk or another part of the body
  • A lump that is growing
  • Pain or tenderness in some cases

Less common symptoms

Symptom Possible cause
Lump in the groin or armpit Lymph node spread
Cough or breathlessness Lung spread
Bone pain Spread to bone
Difficulty swallowing or hoarseness Tumour in the oesophagus or larynx (rare)
Numbness or tingling Pressure on a nearby nerve

When to seek medical advice

See a doctor about any lump that is larger than 5 cm, deep, growing or painful, or a lump that returns after removal.

6. Diagnosis

Test Purpose
MRI of the lump Defines the extent
Core needle biopsy Confirms a granular cell tumour
Complete excision and pathology review Assesses malignancy criteria on the whole tumour
Immunostains Confirm Schwann cell features
Ki-67 and p53 staining Support assessment of risk
CT of the chest and PET-CT Staging
Specialist sarcoma pathology review Strongly recommended

Staging

Staging uses the TNM system for soft tissue sarcoma, considering size, depth, grade, nodal spread and distant spread. Unlike most sarcomas, malignant granular cell tumours spread to lymph nodes relatively often. In a Japanese multicentre study, several patients had lymph node spread at presentation (Imanishi et al., 2016).

7. Treatment

Treatment should be planned by a specialist sarcoma team.

Surgery

Aspect Details
Aim Wide excision with clear margins
Benefit Patients who had surgery lived longer in a registry study (Moten et al., 2018)
Lymph nodes Enlarged nodes are removed; sentinel node biopsy is sometimes considered
Recurrence Further surgery when possible

Even after wide excision, local recurrence can occur. In the Japanese study, three of ten patients treated with wide resection developed a local recurrence (Imanishi et al., 2016).

Radiotherapy

Situation Role
Close or positive margins Reduces the risk of local recurrence
Large, deep tumours Considered before or after surgery
Painful metastases Symptom relief

Drug treatment

Option Notes
Standard sarcoma chemotherapy Responses are uncommon; some patients have long periods of stable disease
Targeted drugs such as pazopanib Tried in individual advanced cases; evidence is limited
Clinical trials Encouraged

In the Japanese series, some patients receiving chemotherapy had stable disease for a year or longer, but all patients with recurrence or spread eventually died of the disease (Imanishi et al., 2016).

Treatment by situation

Situation Typical approach
Atypical tumour, completely removed Close follow-up
Malignant tumour, localised Wide excision, often with radiotherapy
Lymph node spread Lymph node removal and radiotherapy
Distant spread Drug treatment, surgery for selected metastases, symptom control

Recovery after surgery

Period What to expect
First days Pain control, wound care, early movement
2-6 weeks Wound healing; physiotherapy begins
6-12 weeks Gradual return to normal activities
If radiotherapy follows Usually starts 4-8 weeks after surgery, once the wound has healed

Side effects

Treatment Possible side effects
Surgery Wound problems, loss of function, nerve damage, lymphoedema after node removal
Radiotherapy Skin reactions, stiffness, swelling
Chemotherapy Tiredness, hair loss, infection risk, nausea
Targeted drugs Diarrhoea, high blood pressure, liver effects, fatigue

8. Outlook (prognosis)

Study Findings
Fanburg-Smith et al. (1998), 28 malignant cases with follow-up 39% died of disease (median 3 years); local recurrence 32%; metastasis 50%
Moten et al. (2018), 113 SEER patients Five-year cause-specific survival 74%; ten-year 65%
Imanishi et al. (2016), localised malignant cases Five-year overall survival 69%; ten-year 35%

Factors affecting outlook

Factor Effect
Tumour larger than 5 cm Much poorer survival
Metastasis Poorer survival
Surgery Better survival
Necrosis Linked with adverse outcomes
High mitotic activity and Ki-67 above 10% Poorer survival
Older age Poorer survival

Registry data include tumours of all types and sites, which may explain why survival appears better than in pathology series focused on deep soft tissue tumours.

9. Follow-up

Time Typical checks
Years 1-2 Clinic review, MRI of the site and chest CT every 3-4 months
Years 3-5 Every 6 months
After 5 years Yearly; late recurrence is possible
Atypical tumours Close follow-up, as some can spread

10. Living with a malignant granular cell tumour

  • Ask for review in a specialist sarcoma centre
  • Keep follow-up appointments, including chest scans
  • Report new lumps, especially in the groin or armpit, without waiting for your next appointment
  • Work with physiotherapists to restore movement after surgery
  • Manage lymphoedema with compression and exercises if lymph nodes were removed
  • Protect the treated skin from sun if you had radiotherapy
  • Keep a record of your scans, results and treatment dates
  • Seek support from sarcoma charities and support groups

Coping with a rare diagnosis

Being told you have a very rare cancer can feel isolating, and reliable information can be hard to find. Specialist sarcoma nurses can explain test results, coordinate appointments and point you to support. Some people find it helpful to connect with others through rare cancer networks or online communities run by recognised charities.

11. Frequently asked questions

Question Answer
Are all granular cell tumours cancer? No; most are benign
How do doctors know mine is malignant? By microscope criteria, size and behaviour; spread is the definite proof
What does atypical mean? The tumour has one or two worrying features; it usually behaves benignly but needs regular follow-up
Will chemotherapy help? Responses are uncommon, but some patients have long periods of stable disease
Can it come back? Yes, locally or elsewhere, which is why follow-up continues for years
Can I exercise? Yes; gentle, regular activity helps recovery once your wound has healed
Is it inherited? Usually not
I had a benign granular cell tumour removed years ago. Should I worry? Most benign tumours never return as cancer; report any regrowth at the same site
Why are my lymph nodes being checked? This tumour spreads to lymph nodes more often than most sarcomas

12. Questions to ask your care team

  • How many malignancy criteria did my tumour meet?
  • What were the size, margins and Ki-67 results?
  • Has the tumour spread to lymph nodes or elsewhere?
  • Do I need radiotherapy?
  • Is there any role for drug treatment or a clinical trial?
  • How often will I have scans?
  • Should my tumour be reviewed by a second pathologist?
  • Who is my key contact in the sarcoma team?

Resources

  1. Fanburg-Smith, J.C. et al. (1998) ‘Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation’, American Journal of Surgical Pathology, 22(7), pp. 779-794.
  2. Imanishi, J. et al. (2016) ‘Atypical and malignant granular cell tumors in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study’, International Journal of Clinical Oncology, 21(4), pp. 808-816.
  3. Moten, A.S. et al. (2018) ‘Malignant granular cell tumor: clinical features and long-term survival’, Journal of Surgical Oncology, 118(6), pp. 891-897.
  4. Nasser, H. et al. (2011) ‘Malignant granular cell tumor: a look into the diagnostic criteria’, Pathology, Research and Practice, 207(3), pp. 164-168.
  5. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.